|
Feb 19
|
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
|
|
Feb 19
|
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
|
|
Feb 18
|
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
|
|
Feb 17
|
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
|
|
Feb 11
|
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
|
|
Oct 2
|
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
|
Sep 24
|
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
|
|
Aug 29
|
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
|
|
Aug 27
|
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?
|
|
Jul 30
|
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
|
|
Jun 18
|
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
|
|
Dec 27
|
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
|
|
Dec 19
|
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
|
|
Dec 5
|
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
|
|
Nov 30
|
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
|
|
Nov 29
|
GeoVax to Participate in Upcoming December Investor Events
|
|
Nov 28
|
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
|
|
Nov 8
|
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Aug 11
|
GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript
|
|
Aug 10
|
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
|